GlaxoSmithKline is expanding its efforts to encourage research into bioelectronic medicine, putting up $5 million to support R&D projects around the world. …read more Source: GlaxoSmithKline deepens its commitment to ‘electroceuticals’
Johnson & Johnson is taking a deep dive into antivirals, trading $1.75 billion for private biotech Alios BioPharma to get its hands on a midstage treatment and some early assets that could expand its share of the blockbuster hepatitis C market. …read more Source: J&J makes a splash in hep C with a $1.75B deal […]
Regeneron and partner Sanofi have notched another midstage milestone with their in-development allergy drug, a victory that affirms the hypothesis behind a treatment the companies believe could bring in billions. …read more Source: Regeneron’s would-be blockbuster completes the allergic circle with Phase II success
Four months after it signed an option pact that included $33 million in an upfront and early milestone, along with $468 million in add-on incentives, Takeda has agreed to pay the freight on researching up to four more MacroGenics programs while adding up to $400 million each–$1.6 billion in total–in fresh milestones. …read more Source: […]
…read more Source: Baxter inks a big lease in the heart of Cambridge for biotech spinout
Catalyst Pharmaceutical Partners is heralding positive late-stage results for its lead drug, planning to make its case to the FDA in hopes of winning approval for a much-scrutinized orphan treatment. …read more Source: Catalyst soars as its controversial rare disease drug aces Phase III
The U.K.’s Horizon Discovery has snapped up St. Louis-based Sage Labs for $48 million in cash and stock. …read more Source: Of mice and M&A: Horizon buys Sage Labs
Thomson Reuters BioWorld took a deep dive into the subject and surfaced today with a detailed report outlining a bustling new global business with roughly 700 so-called follow-ons put in the clinic by 245 companies and institutions. Looking ahead to 2020, analysts say, you can anticipate that biosimilars will account for about $25 billion out […]
Among the scrum of drugmakers racing forward with a new class of cancer treatments, Bristol-Myers Squibb was the first to win a global regulatory nod and is now first in line for approval in lung cancer, a particularly lucrative indication for the group of promising oncology drugs. …read more Source: Bristol-Myers’ oncology star lines up […]
A new monkey study points to how a cancer treatment that the famous “Berlin patient” underwent may have resulted in HIV being eradicated in his body. …read more Source: How was HIV eradicated in one patient?
